Home > Insider Trading > Filing (0001209191-14-077894)

Filing Details

Accession Number:: 0001209191-14-077894
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2014-12-24 06:05:01
Reporting Period:: 2014-12-23

Filing Date:: 2014-12-24
Accepted Time:: 2014-12-24 06:05:01
Original Submission Date:: 2014-12-23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1594864	Juno Therapeutics Inc.	JUNO	Biological Products, (No Disgnostic Substances) (2836)	463656275

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1281933	K Douglas Bratton	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1536054	Crestline Management, Lp	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1626595	Cl Alaska, L.p.	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1626596	Crestline Investors, Inc.	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1626597	Crestline Si (Gp), L.p.	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-12-23	625,000	$24.00	988,398	No	4	P	Indirect	By CL Alaska, L.P.
Common Stock	Acquisiton	2014-12-23	1,250,000	$0.00	1,250,000	No	4	C	Indirect	By JT Line Partners L.P.
Common Stock	Acquisiton	2014-12-23	68,395	$0.00	1,318,395	No	4	C	Indirect	By JT Line Partners L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By CL Alaska, L.P.
No	4	C	Indirect	By JT Line Partners L.P.
No	4	C	Indirect	By JT Line Partners L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-2 Preferred Stock	Disposition	2014-12-23	1,250,000	$0.00	1,250,000	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-12-23	68,395	$0.00	68,395	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

This amendment has been filed to reflect a correction to the Date of Earliest Transaction and Transaction Date for the purchase of shares on the Form 4 originally filed on December 23, 2014 (the "Original Form 4").
These shares are held directly by CL Alaska, L.P. ("CLA"). The general partner of CLA is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of CLA is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. CLA is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of these shares. CLA, Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own all of these shares. Each such entity and Mr. Bratton disclaim beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. The Original Form 4 correctly reported that following this transaction and all conversion transactions on December 23, 2014, CLA directly holds an aggregate of 25,766,130 shares of Common Stock.
The Original Form 4 incorrectly reported the purchase price for this transaction as $25.00 per share. This amendment has been filed to reflect the correct purchase price of $24.00 per share.
Footnote 5 to the Original Form 4 incorrectly reported that these shares are held directly by CLA. This amendment has been filed to reflect that these shares are held directly by JT Line Partners L.P. ("JT"). The general partner of JT is Bratton Capital Management L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. JT is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of these shares. JT, Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own all of these shares. Each such entity and Mr. Bratton disclaim beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.
The Series A-2 Preferred Stock converted into Common Stock on a 1-for-1 basis immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date.
The Series B Preferred Stock converted into Common Stock on a 1-for-1 basis immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date.